Open AccessPharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis
Author(s) -
RousterStevens Kelly A.,
Gursahaney Aneel,
Ngai Kaleung,
Daru Jennifer A.,
Pachman Lauren M.
Publication year - 2008
Publication title -
arthritis care & research
Language(s) - English
Resource type - Journals
eISSN - 1529-0131
pISSN - 0004-3591
DOI - 10.1002/art.23341
Subject(s) - medicine , juvenile dermatomyositis , pharmacokinetics , prednisolone , methylprednisolone , bioavailability , area under the curve , oral administration , anesthesia , gastroenterology , dermatomyositis , pharmacology
Objective To determine areas under the curve (AUCs) of oral prednisolone (OP) and intravenous methylprednisolone (IVMP) in patients with juvenile dermatomyositis (DM) and assess the association with nailfold end‐row loops (ERLs). Patients with active disease have fewer ERLs that possibly occur in the gastrointestinal tract, impairing absorption of oral medications. Methods Six patients with juvenile DM received 50 mg/m 2 of OP (day 1) and IVMP (day 2). Blood was drawn at baseline and at 5, 15, 30, 45, 60, and 90 minutes, and hourly (hours 2–8) after each dose. Samples were analyzed by reverse‐phase high‐performance liquid chromatography for levels of prednisolone and methylprednisolone. AUCs of OP and IVMP were determined by the trapezoid method; pharmacokinetic parameters were obtained using noncompartmental and compartmental analysis. ERLs were determined from freeze‐frame video microscopy and nailfold capillaroscopy. Results There was a trend toward significance in difference in mean AUC of IVMP (116.72 μg × ml/hour) compared with OP (65.16 μg × ml/hour; P = 0.059). Mean peak concentration was higher for IVMP (34.49 μg/ml) than OP (7.08 μg/ml); mean half‐life was shorter for IVMP (1.90 hours) than OP (2.36 hours). There was an inverse association between ΔAUCs (IVMP AUC − OP AUC) and ERLs (R = −0.68, P = 0.044). Conclusion Patients with juvenile DM and ERL loss may have decreased bioavailability of OP compared with IVMP. This can provide the rationale for greater efficacy of IVMP in patients with active vasculopathy of juvenile DM. Further studies investigating the pharmacokinetics and pharmacodynamics of high‐dose IVMP need to be performed in patients with juvenile DM.